GLP-1 weight loss drugs remain permitted under WADA rules for 2027

The WADA executive committee met last week in Belgrade to, among other things, approve the 2027 prohibited list. Although that list will not be officially published until October, it is already clear what will not be on it.

GLP-1 drugs such as semaglutide (known as Ozempic) and tirzepatide will remain off the prohibited list. These medications are increasingly being used for weight management and therefore play a role in sports where weight classes or body composition are important.

For CrossFit and Hyrox athletes, this means that using these medications will not constitute a doping violation for the time being. The debate over the fairness of such drugs in sport is far from closed, but officially there will be no restrictions in 2027.